Reference no: EM132916587

Assuming that animal studies of a new diagnostic or therapeutic radiopharmaceutical produce encouraging results and that studies in humans can begin, the field is currently limited by a lack of standardization and coordination in clinical trials. In the field of targeted radionuclide therapy, for example, there are currently too many individual clinical trials enrolling too few patients and treating them in widely varying ways. Similarly, clinical trials for diagnostic imaging suffer from different clinical centers using different imaging platforms. This has led to a lack of uniformity in how data are acquired, handled, stored, and interpreted. Building on the experience of cooperative groups, such as the American College of Radiology Imaging Network (ACRIN 2007) and the U.S. FDA, it is important that investigational approaches be standardized so that data can be compared across clinical trials and translated into clinical practice.

1.what is the best relationship generated by the Auxotrophic mutant and the yeast plasmid recombinant?
2.show the replication criteria for the REP1 and REP2 genes
3.propose the conspicuous size of the 2 micrometer circle?
4.relate the plasmid to the 2 micrometer circle
5.justify accordingly; Plasmids are present in eukaryotes.
6.to which categorization can the best fit of Saccharomyces cerevisiae apply?
7. interrelate the Large scale production to the cloning vector
8.explain on the YEP as the highest efficiency of transformation
9. Why is a high transformation frequency needed?make sure you explain
10.explain the decision criteria between the Choice of vector and the Transformation frequency